2,845 Shares in Insmed, Inc. (NASDAQ:INSM) Bought by Whalen Wealth Management Inc.

Whalen Wealth Management Inc. purchased a new stake in Insmed, Inc. (NASDAQ:INSM - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,845 shares of the biopharmaceutical company's stock, valued at approximately $217,000.

Several other hedge funds have also added to or reduced their stakes in the business. Principal Securities Inc. raised its position in shares of Insmed by 55.5% in the fourth quarter. Principal Securities Inc. now owns 3,139 shares of the biopharmaceutical company's stock valued at $217,000 after purchasing an additional 1,120 shares during the period. Sanctuary Advisors LLC boosted its holdings in shares of Insmed by 13.7% during the 4th quarter. Sanctuary Advisors LLC now owns 3,861 shares of the biopharmaceutical company's stock worth $295,000 after buying an additional 464 shares during the period. CIBC Asset Management Inc grew its stake in Insmed by 5.6% in the 4th quarter. CIBC Asset Management Inc now owns 4,685 shares of the biopharmaceutical company's stock valued at $323,000 after buying an additional 247 shares during the last quarter. Truist Financial Corp raised its holdings in Insmed by 3.4% in the 4th quarter. Truist Financial Corp now owns 30,038 shares of the biopharmaceutical company's stock valued at $2,074,000 after acquiring an additional 1,000 shares during the period. Finally, Venturi Wealth Management LLC bought a new position in Insmed in the 4th quarter valued at about $86,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Leerink Partners boosted their price objective on Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, June 10th. Royal Bank Of Canada lifted their price target on Insmed from $99.00 to $106.00 and gave the stock an "outperform" rating in a report on Wednesday, June 11th. Citigroup raised Insmed to a "buy" rating in a report on Tuesday, June 10th. HC Wainwright increased their price objective on Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. Finally, Mizuho lifted their target price on Insmed from $96.00 to $110.00 and gave the stock an "outperform" rating in a report on Wednesday, June 11th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $106.80.

Insider Activity

In related news, Director Clarissa Desjardins acquired 1,895 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was acquired at an average cost of $66.87 per share, for a total transaction of $126,718.65. Following the transaction, the director now directly owns 1,895 shares in the company, valued at $126,718.65. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William Lewis sold 6,830 shares of the stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total transaction of $479,192.80. Following the completion of the transaction, the chief executive officer now directly owns 233,924 shares of the company's stock, valued at approximately $16,412,107.84. The trade was a 2.84% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 488,752 shares of company stock worth $43,199,826. Insiders own 3.00% of the company's stock.

Insmed Price Performance

INSM stock traded down $3.11 during mid-day trading on Thursday, hitting $101.74. The stock had a trading volume of 3,949,206 shares, compared to its average volume of 2,180,695. The firm has a fifty day simple moving average of $77.47 and a 200 day simple moving average of $75.35. The firm has a market capitalization of $19.30 billion, a P/E ratio of -17.10 and a beta of 0.80. The company has a current ratio of 5.86, a quick ratio of 5.44 and a debt-to-equity ratio of 11.38. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $106.83.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The firm had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. During the same period last year, the business earned ($1.06) earnings per share. The business's revenue was up 22.9% compared to the same quarter last year. As a group, research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.